MAAAs help guide treatment of women's health issues | Study finds triglycerides in LDL may predict CV events | Study identifies origins of Alzheimer's disease
ADVERTISEMENT
July 17, 2018
AACC SmartBrief
SIGN UP ⋅   FORWARD
Top Story
MAAAs help guide treatment of women's health issues
New research highlights the benefits of multianalyte assays with algorithmic analyses to guide treatment of women's health issues, including breast cancer and preeclampsia. MAAAs use an algorithm to combine two or more biochemical or molecular markers, as well as patient information and demographics, to provide a personalized risk assessment.
Clinical Laboratory News (7/2018) 
LinkedIn Twitter Facebook Google+ Email
Improve Quality and Reduce Costs with CLSI
Let CLSI help your lab implement a cost-cutting, quality-focused plan with easy-to-understand and use quality management system (QMS) guidance. CLSI's QMS products can show you how to prepare for accreditation, improve staff training, and manage errors. Visit us to learn more.
ADVERTISEMENT
Science Briefs
Study finds triglycerides in LDL may predict CV events
Triglycerides in low-density lipoprotein cholesterol may predict cardiovascular events and are associated with genetic variants, researchers reported in the Journal of the American College of Cardiology. "Our next step will be to see how lifestyle modifications or medications affect LDL-TG levels and if that affects outcomes of cardiovascular disease," said Baylor College of Medicine researcher Anum Saeed.
Healio (free registration) (7/10) 
LinkedIn Twitter Facebook Google+ Email
Study identifies origins of Alzheimer's disease
Researchers at University of Texas Southwestern Medical Center found that tau molecules associated with Alzheimer's disease change shape before attaching to other tau proteins and enabling tau tangle formation, and aren't indistinctly shaped and harmful only when attached to other tau proteins, as previously believed. The findings in the journal eLife may allow early Alzheimer's detection and has prompted the development of therapies aimed at balancing tau before they change their shape, researchers said.
KXAS-TV (Dallas-Fort Worth) (7/11),  Medical Xpress/University of Texas Southwestern Medical Center (7/10) 
LinkedIn Twitter Facebook Google+ Email
Online MS in Individualized Genomics & Health
Advance your career with an online MS in Individualized Genomics and Health from Johns Hopkins Advanced Academic Programs. This fully online, part-time degree provides the multidisciplinary skills needed to lead this rapidly growing area of research and applied science. Find Out More
ADVERTISEMENT
Tech Briefs
Sight Diagnostics' point-of-care blood Dx system released to Europe
Israel-based medical devices startup Sight Diagnostics has released in Europe the OLO point-of-care blood diagnostics system, which allows AI-powered blood testing to be done in a doctor's office. The system, which the company hopes to get FDA approval for next year, digitizes blood into specifically colored microscope images and determines and counts blood cell types using proprietary machine vision algorithms.
TechCrunch (7/12) 
LinkedIn Twitter Facebook Google+ Email
Practice Briefs
FDA clears Quidel's whooping cough assay
The FDA has granted Quidel 510(k) clearance for its Solana Bordetella Complete Assay, a molecular diagnostic test designed for detecting and differentiating whooping cough-causing Bordetella species collected on nasopharyngeal swabs. The assay operates on the company's Solana system that uses helicase-dependent amplification and allows up to 12 samples to be processed for every batched run.
GenomeWeb Daily News (free registration) (7/16) 
LinkedIn Twitter Facebook Google+ Email
FDA allows expanded use of Roche's procalcitonin assay
Roche Holding has secured expanded clearance from the FDA for its Elecsys BRAHMS PCT assay for use in antibiotic treatment decisions. The electrochemiluminescence immunoassay, which measures serum or plasma levels of procalcitonin, was previously cleared for assessment of progression to septic shock and severe sepsis, as well as 28-day post-diagnosis mortality.
360Dx (tiered subscription model) (7/13) 
LinkedIn Twitter Facebook Google+ Email
Business/Corporate Briefs
Kypha announces acquisition of Biosensia
Kypha, a St. Louis-based diagnostics firm that makes biomarker tests for the assessment of immune status and inflammation, has paid an undisclosed amount for Biosensia, an Irish diagnostics platform and contract-development company. The acquisition makes Biosensia, developer of the RapiPlex point-of-care diagnostic system, a wholly owned subsidiary of Kypha.
360Dx (tiered subscription model) (7/16) 
LinkedIn Twitter Facebook Google+ Email
Funding round brings $9M for XaTek to advance portable ClotChip
XaTek's series A financing round has brought in $9.1 million to further development of a device that can quickly analyze blood clotting ability with a single drop. The device, called ClotChip, will now be tested in clinical trials.
Hemophilia News Today (7/16) 
LinkedIn Twitter Facebook Google+ Email
AACC News
Free Webinar: Hepatitis B: Diagnostic Challenges
There's growing need to monitor of immunosuppressed patients with ultra-sensitive diagnostic tools that can identify HBV reactivation. Join Patricia Slev, PhD on July 26 as she discusses current testing algorithms and the latest Hepatitis B virus guidelines.
LinkedIn Twitter Facebook Google+ Email
The Role of Point-of-Care Testing in a Value-Based Healthcare Landscape: 27th AACC International CPOCT Symposium
September 26 - 29, 2018 Washington, DC, USA Learn how point-of-care testing contributes to healthcare value through faster result turnaround time, lower testing costs, and improved patient outcomes.
LinkedIn Twitter Facebook Google+ Email
Learn more about AACC:
AACC Homepage | AACC Membership | Annual Meeting
Clinical Laboratory News | Clinical Chemistry
Sign Up
SmartBrief offers 200+ newsletters
Advertise
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Contributing Editor  -  Genna Rollins
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  April Hollis
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2018 SmartBrief, Inc.®
Privacy Policy (updated May 25, 2018) |  Legal Information